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Nuclear Accumulation of Truncated Atrophin-1
Fragments in a Transgenic Mouse Model of DRPLA
of DRPLA are similar to those of Huntington's disease
(HD) and include chorea (and other involuntary move-
ments), ataxia, incoordination, and dementia (Smith et
Gabriele Schilling,1,10 Jonathan D. Wood,1,10 Kui Duan,1
Hilda H. Slunt,2 Vicky Gonzales,2 Mitsunori Yamada,7
Jillian K. Cooper,1 Russell L. Margolis,1
al., 1958; Naito and Oyanagi, 1982; Ross et al., 1997a,Nancy A. Jenkins,6 Neal G. Copeland,6
1997b). The disease is caused by an expansion of aHitoshi Takahashi,7 Shoji Tsuji,8 Donald L. Price,2,3,4
highly polymorphic CAG repeat in the coding region ofDavid R. Borchelt,2,9 and Christopher A. Ross1,3.5,9
the atrophin-1 gene. The repeat length for atrophin-11Division of Neurobiology
ranges from 6 to 35 CAG repeats in unaffected individu-Department of Psychiatry
als and from 49 to 88 CAG repeats in DRPLA cases2Department of Pathology and
(Koide et al., 1994; Nagafuchi et al., 1994a). JuvenileDivision of Neuropathology
cases of DRPLA, which are associated with expansions3Department of Neuroscience
.60 CAG repeats, tend to show fewer involuntary move-4Department of Neurology
ments and have a high incidence of seizures (Ross et5Program in Cellular and Molecular Medicine
al., 1997b).The Johns Hopkins University School of Medicine
Neuropathological characteristics of the disease areBaltimore, Maryland 21205
loss of neurons and gliosis in several areas of the brain,6Mammalian Genetics Laboratory
including the dentate nucleus of the cerebellum, redNational Cancer Institute Cancer Center
nucleus, globus pallidus, and subthalamic nucleus (NaitoFrederick, Maryland 21702
and Oyanagi, 1982; IIzuka et al., 1984; Takahashi et al.,7Department of Pathology
1988; Becher et al., 1997; Ross et al., 1997a, 1997b).8Department of Neurology
These neurons, as well as many other populations ofBrain Research Institute
neurons, show ubiquitin-immunoreactive nuclear inclu-Niigata University
sion bodies (Becher et al., 1998; Hayashi et al., 1998;Niigata 951
Igarashi et al., 1998).Japan
DRPLA and HD are members of a growing family of
polyglutamine repeat diseases that also include spinal
and bulbar muscular atrophy and several forms of
Summary spinocerebellar ataxia (The Huntington's Disease Col-
laborative Research Group, 1993; Orr et al., 1993; Banfi
et al., 1994; Koide et al., 1994; Nagafuchi et al., 1994b;Dentatorubral and pallidoluysian atrophy (DRPLA) is a
Gusella and MacDonald, 1996; Paulson and Fischbeck,member of a family of progressive neurodegenerative
1996). These diseases share many common features,diseases caused by polyglutamine repeat expansion.
such as anticipation, repeat instability, and widespreadTransgenic mice expressing full-length human atro-
expression of the gene product, with neuronal loss re-phin-1 with 65 consecutive glutamines exhibit ataxia,
stricted to distinct subsets of neurons. DRPLA patientstremors, abnormal movements, seizures, and prema-
(like patients with the other diseases) show restrictedture death. These mice accumulate atrophin-1 immu-
neurodegeneration despite widespread expression ofnoreactivity and inclusion bodies in the nuclei of
the gene product in the brain and peripheral tissuesmultiple populations of neurons. Subcellular fraction-
(Nagafuchi et al., 1994a; Margolis et al., 1996).ation revealed 120 kDa nuclear fragments of mutant
The atrophin-1 gene was initially cloned as CTG-B37atrophin-1, whose abundance increased with age and
by screening of brain cDNA libraries for CAG repeatsphenotypic severity. Brains of DRPLA patients con-
(Li et al., 1993). It encodes a protein, atrophin-1, with atained apparently identical 120 kDa nuclear fragments.
calculated molecular mass of 125 kDa and an apparentBy contrast, mice overexpressing atrophin-1 with 26
molecular mass of z200 kDa on SDS±PAGE (Yazawaglutamines were phenotypically normal and did not
et al., 1995; Miyashita et al., 1997; Wood et al., 1998).accumulate the 120 kDa fragments. We conclude that
Atrophin-1 contains several regions with simple repeti-the evolution of neuropathology in DRPLA involves
tive sequences, including a serine-rich region, a poly-proteolytic processing of mutant atrophin-1 and nu-
proline tract, and a region of alternating acidic andclear accumulation of truncated fragments.
basic residues, in addition to the polyglutamine repeat.
Atrophin-1 has been reported to have cytoplasmic and
nuclear distributions in neurons (Yazawa et al., 1995).Introduction
To examine the biology of mutant atrophin-1 in vivo,
we have now generated transgenic mouse lines ex-Dentatorubral and pallidoluysian atrophy (DRPLA) is an
pressing full-length atrophin-1 with 65 or 26 glutaminesautosomal dominant progressive neurodegenerative dis-
(AT-FL-65Q and AT-FL-26Q, respectively). Expressionorder that usually manifests in midlife. The symptoms
of the transgene was driven by the mouse prion pro-
tein promoter, which expresses in a copy number±
dependent and integration site±independent manner in9 To whom correspondence should be addressed (e-mail: caross@
CNS neurons and some peripheral tissues (Borchelt etjhu.edu [C. A. R.], drbor@welchlink.welch.jhu.edu [D. R. B.]).
10 These authors contributed equally to this work. al., 1996). Several lines of AT-FL-65Q mice showed a
Neuron
276
Figure 1. Phenotypic Analysis of DRPLA
Transgenic Mice
(A) Vector map of MoPrP.AT-FL-26Q/65Q.
Full-length atrophin-1 cDNAs (with no epi-
tope tags) encoding 26 or 65 consecutive glu-
tamines ([Q]n) were flanked with XhoI linkers
and subcloned into the mouse prion protein
promoter (Pro) vector (MoPrP.Xho). The non-
coding portions of the second and third ex-
ons (E2 and E3) of the PrP gene were fused
into one exon that contains the atrophin-1
cDNA insert (with its own start and stop co-
dons). The genomic PrP sequences are
cloned into the NotI site of pBluescript SK1
(pBS).
(B) Long exposure photograph of a 6.5-
month-old AT-FL-65Q-150 mouse and an
age-matched AT-FL-26Q-79 mouse, illustrat-
ing the resting tremor seen in AT-FL-65Q
mice. Other phenotypic characteristics in-
clude jerky movements, ataxic gait, low
weight, seizures, hindlimb clasping, poor
breeding, and premature death.
(C) Rotating rod analysis showing that the
performance of AT-FL-65Q-150 mice at 4
months of age was very impaired compared
with age-matched AT-FL-26Q-79 mice and
nontransgenic mice.
(D) Death curves for AT-FL-65Q-82, AT-FL-
65Q-150, and AT-FL-26Q-84, illustrating pre-
mature death of mutant transgenic mice.
progressive neurological phenotype that includes ataxia, processing and accumulation of the mutant polyglutamine
protein as pathologic mechanisms in a transgenic mouseinvoluntary movements, tremors, seizures, and prema-
ture death. The brains of affected mice contained accu- model of a trinucleotide repeat disorder.
mulations of atrophin-1 immunoreactivity in the nuclei
of multiple populations of neurons, including the dentate Results
nucleus and granular layer of the cerebellum, cochlear
nucleus, pons, regions of basal ganglia, and cortex. The DRPLA 65Q Mice Exhibit a Progressive
Neurological Phenotypenuclei of most neurons exhibiting nuclear staining also
contained atrophin-1-immunoreactive inclusions. The We generated transgenic mice that express full-length
human atrophin-1 with 26 glutamines (normal, AT-FL-temporal and spatial distribution of the nuclear immuno-
reactivity in the mice correlated well with the appearance 26Q) and 65 glutamines (mutant, AT-FL-65Q) under the
transcriptional control of the mouse prion protein pro-and accumulation of 120 kDa fragments of mutant
atrophin-1. Furthermore, apparently identical mutant moter, which expresses in neurons throughout the brain
(Borchelt et al., 1996) (Figure 1A). Thirty-eight AT-FL-atrophin-1 fragments were present in the brains of
DRPLA cases. We conclude that the evolution of patho- 65Q founders were obtained, several of which showed
frequent seizures and died prematurely. Nevertheless,logical changes in DRPLA involves proteolytic pro-
cessing of mutant atrophin-1 to generate fragments that we were able to establish several lines of AT-FL-65Q
mice in which levels of expression and behavioral phe-preferentially accumulate and aggregate in the nucleus.
This work represents a definitive example of proteolytic notypes were examined. Only AT-FL-26Q founders with
DRPLA Transgenic Mouse Model
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Figure 2. Transgene Expression of DRPLA Transgenic Mice
(A) Northern blot analysis of transgene expression in transgenic lines. The highest expression of the transgene mRNA was seen in the control
lines AT-FL-26Q-79 and AT-FL-26Q-84. Severalfold lower expression of mRNA was observed in the mutant lines AT-FL-65Q-79, AT-FL-65Q-
82, and AT-FL-65Q-150. These three mutant lines showed a similar early onset phenotype before 2 months. Lower expressing AT-FL-65Q
lines (124, 125, and 165) gave late symptoms (onset, 8±12 months of age). Endogenous mouse atrophin-1 mRNA was not detected at the
hybridization stringency used. The blot was reprobed with a fragment of the mouse prion protein cDNA to verify equal loading of RNA in each
lane (lower panel).
(B) Immunoblot analysis of total homogenates (H), cytosol (C), and preparations enriched in nuclei (N) from age-matched nontransgenic, AT-
FL-26Q-84, and AT-FL-65Q-150 mouse brains. The equivalence of loading was confirmed by Coomassie blue staining of an identically loaded
gel (data not shown). This gel also confirmed the efficiency of separation of nuclear and cytoplasmic proteins into the different subcellular
fractions. The upper panel shows an immunoblot probed with the anti-atrophin-1 antibody AP142. In nontransgenic mouse brain samples,
atrophin-1 was highly enriched in the cytosol but was also present in the fraction enriched in nuclei. Homogenates from AT-FL-65Q-150
contained distinct 120 kDa fragments (indicated with an arrow), in addition to full-length endogenous mouse and transgene-derived human
atrophin-1. The 120 kDa fragments were highly enriched in the nuclear fraction, while full-length atrophin-1 polypeptides predominated in the
cytosol. Note the smearing of atrophin-1 immunoreactivity in the nuclear fraction, indicative of aggregation. Comparison of full-length atrophin-1
levels in AT-FL-26Q-84 and AT-FL-65Q-150 homogenates and cytosol demonstrates that protein expression is higher in the wild-type than
in the mutant transgenic mice, in agreement with the Northern blot data. Full-length atrophin-1 predominated in AT-FL-26Q-84 nuclei and
cytosol, although a prominent 150 kDa band (marked with an asterisk) was observed, and there was also faint immunoreactivity around 120
kDa in the nuclear fraction. The middle panel shows an identically loaded immunoblot probed with the expanded polyglutamine-specific
monoclonal antibody 1C2. The 120 kDa fragments (indicated with an arrow) are detected with 1C2, confirming that they contain the expanded
polyglutamine tract. The lower panel shows an immunoblot probed with an anti-TBP antibody (N-12; Santa Cruz Biotechnology) to confirm
enrichment of nuclear proteins in the nuclear preparations.
the highest numbers of transgene copies were bred, were observed in some animals, particularly in lines 82
and 150, and may contribute to premature death. Over-and we have maintained a number of lines of mice that
have the highest levels of transgene-derived mRNA (see all, the behavioral phenotype of the mice closely resem-
bles that of the human disease. Adult DRPLA patientsbelow). AT-FL-26Q mice have remained indistinguish-
able from nontransgenic littermates for more than 18 show involuntary movements (including chorea and in-
tention tremors), ataxia, and dementia (Smith et al.,months.
Mice expressing AT-FL-65Q (lines 79, 82, and 150) 1958; Naito and Oyanagi, 1982), and juvenile onset
DRPLA patients often have seizures (Ross et al., 1997a,exhibited a progressive phenotype consisting of invol-
untary tremors (Figure 1B), ataxic gait, and loss of coor- 1997b). The length of the polyglutamine tract in our mice
is typical of that seen in juvenile cases (Koide et al.,dination (Figure 1C), consistent with dysfunction of the
cerebellum (and other brain regions), beginning at 1±2 1994; Ikeuchi et al., 1995; Komure et al., 1995).
months of age. The 65Q mice showed other behavioral
signs, including hyperactivity, increased aggression,
and lower breeding efficiency. The phenotypes were Expression of Normal and Expanded Atrophin-1
in Transgenic Miceconsistent among the different lines of mice, with the
only variable being the age of onset. Death curves (Fig- Northern blot analysis of transgene-derived mRNA
levels (Figure 2A) indicated that mice expressing AT-ure 1D) illustrate premature death of AT-FL-65Q lines 82
and 150, compared with AT-FL-26Q controls. Seizures FL-26Q (lines 79 and 84) showed the highest levels of
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expression, greater than that in mice expressing AT-FL- strated that in the mutant mice, the fragments contained
65Q (lines 79, 82, and 150). A signal for endogenous the expanded glutamine tract (Figure 2B, middle panel).
mouse atrophin-1 mRNA was not detected at the hybrid- These fragments were also recognized by an antibody
ization stringency used. These Northern blots demon- to the N terminus (residues 1±15) of atrophin-1 (data not
strate a single transgene mRNA species. The onset of shown).
symptoms correlated well with the levels of mutant mRNA.
Mice expressing lower levels of mutant atrophin-1 (lines Intranuclear Inclusions and Diffuse Nuclear Labeling
124, 125, and 165; see Figure 2A) developed symptoms in Mutant Atrophin-1 Mice
at about 8±12 months of age, whereas mice expressing Histological analysis of several severely affected, 12-
higher levels (lines 79, 82, and 150) developed symptoms month-old 65Q mice did not reveal abnormalities in pe-
between 1 and 2 months of age. ripheral tissues, including liver, pancreas, kidney, lung,
and skeletal muscle. Although there were a few intra-
Nuclear Localization and Proteolytic Processing nuclear inclusions in heart (data not shown), a tissue in
of 65Q Atrophin-1 which the prion promoter expresses well, histological
To assess the subcellular distribution of 26Q and 65Q preparations of heart were normal. Inclusions were ab-
atrophin-1 protein in the brains of these animals, total sent in skeletal muscle (data not shown). The resting
homogenates, cytosol, and nuclei were prepared blood glucose levels in 12-month-old 65Q mice were
from nontransgenic, AT-FL-26Q-84, and AT-FL-65Q-150 normal (baseline glucose levels were measured at 154 6
mouse brains and analyzed by immunoblotting with the 23 and 169 6 23 mg.dl21 in 13-month-old AT-FL-65Q-
anti-atrophin-1 antibody AP142 (Wood et al., 1998) (di- 150 mice [n 5 4] and age-matched nontransgenic con-
rected against residues 425±439, which are 100% con- trols [n 5 3], respectively).
served between mouse and human; Figure 2B, upper Overall, the brains of the AT-FL-65Q transgenic mice
panel). Comparison of full-length atrophin-1 immunore- appeared to be grossly normal. In the brains of several
activity in total homogenates (Figure 2B, upper panel, endstage mice, there did not appear to be increased
lanes 1, 4, and 7) suggests that AT-FL-26Q-84 mice labeling for glial fibrillary acidic protein, indicating that
express five to ten times the level of endogenous there was no reactive gliosis. Silver impregnation indi-
atrophin-1, while AT-FL-65Q-150 mice (the line most cated a normal cytoskeletal architecture (data not shown).
extensively analyzed in the present study) appeared to However, immunohistochemical staining of symptom-
express a level comparable to that of endogenous atic AT-FL-65Q brain with AP142 revealed diffuse nu-
atrophin-1. The lower levels of transgene-derived mRNA clear staining of variable frequency and intensity through-
in the AT-FL-65Q-150 mice as compared with either of out the brain (Figures 3A±3K), similar to what is seen in
the two lines of AT-FL-26Q mice (see Figure 2A) support DRPLA patients (Becher et al., 1997; Hayashi et al.,
the idea that the levels of mutant protein expression are 1998). In our AT-FL-65Q mice, nuclei in the cerebellum
lower than the AT-FL-26Q expression levels. Assessing and cortex showed very strong immunoreactivity (Fig-
the total level of transgene products in these animals is ures 3A±3C and 3J), whereas relatively few nuclei in
difficult, as both 26Q and 65Q atrophin-1 are subject to striatum (Figure 3G), olfactory bulb (Figure 3K), and
proteolytic processing. Moreover, the abundance of the
brainstem (Figure 3E) were immunoreactive with AP142.
120 kDa fragments in the 65Q mice increases with age
The immunoreactivity in the cerebellar dentate nucleus
(see below). On the basis of the relative abundance
of two independent AT-FL-65Q lines (lines 82 and 150)of the full-length transgene-derived protein levels, we
exhibited similar nuclear labeling and inclusions (Figuresconclude that the line 150 mice express a level compara-
4A and 4C). All atrophin-1 immunoreactivity could be com-ble to or slightly greater than that of endogenous
peted out completely by preincubation with the peptideatrophin-1.
antigen (Figures 4B and 4D). Nuclear immunostaining wasSubcellular fractionation studies of total brain homog-
much less intense in mice expressing AT-FL-26Q (Figureenates demonstrated that both endogenous and human
4E), even though these mice express higher levels of26Q atrophin-1 were predominantly cytosolic, with a
mRNA and protein than the mutant mice (see Figuresmaller fraction detected in preparations enriched for
2A). Nontransgenic mice exhibited diffuse nuclear andnuclei (Figure 2B). In mice expressing high levels of
cytoplasmic labeling (Figure 4F), consistent with the re-human 26Q atrophin-1, there were proteolytic fragments
sults from subcellular fractionation (see Figure 2B).of the normal protein, with the predominant species
Intranuclear inclusions in DRPLA postmortem brainshowing an apparent mass of 150 kDa and a minor
were detectable with an anti-ubiquitin antibody (Becherspecies of 120 kDa. In cell transfection experiments,
et al., 1998; Hayashi et al., 1998; Igarashi et al., 1998).a 150 kDa band is always apparent when normal and
In contrast, immunostaining of paraffin sections fromexpanded forms of atrophin-1 are overexpressed (Wood
endstage AT-FL-65Q mouse brain with two differentet al., 1998). The larger fragments were largely localized
anti-ubiquitin antibodies did not reveal intranuclear in-to the cytosol (Figure 2B, upper panel, asterisk). Small
clusions (data not shown). It is possible that the epitopeamounts of 120 kDa fragment were present in the nu-
was hidden in mouse brains or that ubiquitination occursclear fraction of mice expressing AT-FL-26Q. In 65Q
very late in the disease.(line 150) mice, both full-length mutant protein and pro-
Neuropil aggregates have been observed in severalteolytic fragments were detected; the prominent proteo-
areas of brain from HD patients and HD transgeniclytic fragments showed a relative mass of 120 kDa and
mouse models (DiFiglia et al., 1997; Reddy et al., 1998;were entirely localized to the nucleus (Figure 2B). Immu-
Gutekunst et al., 1999; Schilling et al., 1999). Immuno-noblotting with an antibody specific for expanded poly-
glutamine tracts (1C2) (Trottier et al., 1995) demon- staining with our atrophin-1 antibody failed to recognize
DRPLA Transgenic Mouse Model
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Figure 3. Intense Diffuse Nuclear Staining and Intranuclear Inclusion Bodies in Different Brain Regions of AT-FL-65Q Mice
Immunostaining of sections of paraffin-embedded brains of AT-FL-65Q F3 offspring with AP142 (1:10,000) demonstrated intense diffuse
nuclear staining and a high density of nuclear inclusions in the dentate nucleus (A), molecular cell layer (B), and granule cell layer (C) of the
cerebellum, as well as in cochlear nucleus (D), thalamus (F), amygdala (H), hippocampus (I), and cortex (J). Inclusions were less frequent or
absent in the brainstem (E), striatum (G), and olfactory bulb (K). The polyglutamine antibody 1C2 detected inclusions in an endstage founder
in the trigeminal nucleus of the brainstem (l). (A), (B), (C), (D), and (H) are from a 4.5-month-old AT-FL-65Q-82 animal, while (E), (F), (G), (I), (J),
and (K) are from a 9-month-old AT-FL-65Q-150 animal. Original magnification was 2633 for (A) through (G) and 1603 for (J) through (I).
neuropil aggregates in 65Q mouse brain sections, when by immunoblotting and immunostaining with AP142.
Data from 1-month-old and 11-month-old animals areanalyzed by light microscopy, suggesting that aggrega-
tion might be a solely nuclear event. shown in Figure 5. Between 1 and 11 months of age,
there was a dramatic increase in the levels of the 120To determine the relationship between nuclear staining,
nuclear inclusions, and atrophin-1 processing, we exam- kDa fragments (Figure 5A). There was also marked in-
crease in high molecular weight±immunoreactive spe-ined the temporal and spatial distribution of mutant atro-
phin-1 fragments. Nuclei were prepared from AT-FL-65Q- cies, which may represent aggregated or modified spe-
cies of the mutant fragments. The 11-month-old animals150 brains at several different time points and analyzed
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Figure 4. Atrophin-1 Localization in the Den-
tate Nucleus of the Cerebellum
Immunohistochemical staining of sagital sec-
tions of paraffin-embedded tissue with the poly-
clonal, anti-peptide antibody AP142 (1:10,000)
reveals intense nuclear staining and dense
intranuclear inclusion bodies (marked by ar-
rowheads), in the dentate nucleus of the cere-
bellum in lines AT-FL-65Q-82 (4.5 m) (A) and
AT-FL-65Q-150 (9 m) (C). The inset shows
that the inclusion bodies in the dentate nu-
cleus are more readily visualized by further
dilution of the antibody to 1:25,000. All of the
staining in lines AT-FL-65Q-82 (B) and AT-
FL-65Q-150 (D) was abolished by preincuba-
tion of AP142 with the corresponding peptide
antigen, demonstrating that the diffuse nuclear
immunostaining represents specific labeling.
Staining of equivalent sections from the con-
trol line AT-FL-26Q-79 (E) revealed a combi-
nation of general cytoplasmic and punctate
nuclear staining but no nuclear inclusion bod-
ies that are distinct from nucleoli or chromatin
fragments (small dark blue structures in some
nuclei). Little or no atrophin-1 immunoreactiv-
ity was detected in nontransgenic mice under
the conditions optimal for visualizing the anti-
gen in mutant transgenic mice (F). Original
magnification was 2633. Obvious neuronal
loss was not observed in the dentate nucleus
of the cerebellum. It is possible that small
losses (20%±30%) may have occurred. Ster-
eologic cell counts on multiple animals will
be required to determine the extent of cell
loss.
show severe tremor and ataxia, while the 1-month-old seen in the 65Q mice is a consequence of the generation
and accumulation of the 120 kDa fragments.animals show no tremor or ataxia. Immunocytochemical
stains of 1- and 11-month-old animals show that the
relative frequency of immunostained nuclei increases in Proteolytic Processing of Atrophin-1
concert with the increase in the level of the mutant pro- in DRPLA Patients
tein (data not shown). An examination of the regional To determine whether the accumulation of truncated
distribution of the 120 kDa fragments in P1 fractions atrophin-1 products could be relevant to the human
of brains from symptomatic AT-FL-65Q-150 (Figure 5B) condition, enriched nuclear fractions were prepared from
demonstrated a direct correlation with the distribution frozen pieces of human DRPLA and non-DRPLA cerebella.
of diffuse nuclear atrophin-1 immunoreactivity seen in On immunoblot analysis with AP142, a banding pattern
immunohistochemical analyses (see Figure 3). In cere- similar to that seen in AT-FL-65Q mice was observed,
bellum and cortex, which show very intense nuclear including the 120 kDa fragments, high±molecular weight
immunostaining, the 120 kDa fragments were more (.200 kDa) bands, and high±molecular weight smearing,
abundant than the full-length transgene protein. The region which began at around 120 kDa, as in AT-FL-65Q mouse
with the highest level of 120 kDa fragments was the cere- brain samples (Figure 6). In control cases, a single band
bellum. In olfactory bulb and brainstem, where fewer nuclei around 200 kDa was observed. Immunoblotting with 1C2
showed intense nuclear immunostaining, the levels of the confirmed that the 120 kDa fragments contained the
120 kDa fragments were relatively low. Collectively, these expanded polyglutamine tract (data not shown). Diffuse
nuclear labeling, similar to that observed in AT-FL-65Qdata strongly suggest that the nuclear immunostaining
DRPLA Transgenic Mouse Model
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Figure 6. Immunoblot Analysis of Nuclear Protein Extracts from Hu-
man Cerebellar Cortex Samples and Whole Transgenic Mouse
Brains
Seemingly identical 120 kDa fragments were seen in the DRPLA
patient and in AT-FL-65Q transgenic mouse samples. Shorter expo-
sure resolved the large 120 kDa band in the AT-FL-65Q sample lane
into two distinct bands. High±molecular weight (.200 kDa) bands
and high±molecular weight smearing were seen in both DRPLA pa-
tients and AT-FL-65Q mice. A single band at z200 kDa was seen
in the control nuclear extracts. Labeling of the blots with antibodies
to poly-ADP-ribose polymerase (a mostly nuclear protein) and glyc-
eraldehyde 3-phosphate dehydrogenase (a mostly cytoplasmic pro-
tein) confirmed the efficiency of separation into nuclear and cyto-
plasmic fractions (data not shown). Details regarding the patient
and control tissues are provided in the Experimental Procedures.
the symptoms of which include tremors and other abnor-
mal movements, ataxia, incoordination, seizures, and
premature death. The brains of these animals appear
grossly normal, but nuclei of multiple neuronal popula-
tions accumulate aberrant atrophin-1 immunoreactivity
Figure 5. Temporal Accumulation of 120 kDa Fragments in AT-FL- and atrophin-1-immunoreactive inclusions. The tempo-
65Q-150 Brain ral and spatial distribution of nuclear atrophin-1 immu-
(A) Nuclei were prepared from the whole brains of individual mice noreactivity correlated with the appearance and accu-
and analyzed by immunoblotting for atrophin-1. The 120 kDa frag-
mulation of 120 kDa fragments of mutant protein. Thements were detected in nuclei from the 1-month-old animal (indi-
appearance of the 120 kDa fragments precedes the ap-cated with an arrow) but were much more abundant in nuclei from
pearance of overt behavioral symptoms, and the levelsthe 11-month-old animal. Equivalence of loading was confirmed by
Coomassie blue staining of an identically loaded gel (right panel). of the fragments increase as the course of the disease
(B) Regional distribution of 120 kDa atrophin-1 fragments in AT-FL- progresses. Apparently identical fragments of mutant
65Q-150 mouse brains. Three mouse brains were dissected, specific atrophin-1 were detected, albeit at lower levels, in
regions were pooled, and P1 fractions were prepared as described
nuclear extracts from cerebella of DRPLA patients. Inin the Experimental Procedures. Protein (20 mg) was loaded to each
addition to the 120 kDa fragments, higher±molecularlane, except for brainstem and olfactory bulb, where 40 mg was
weight bands (.200 kDa) and smearing of immunoreac-loaded. The 120 kDa fragments were most prominent in cerebellum
and least prominent in brainstem and olfactory bulb, even with dou- tivity were observed in all AT-FL-65Q brain nuclear prep-
ble the loading compared with the other regions. arations. The higher bands could result from the action
of transglutaminases or from covalent modification with
ubiquitin-like molecules, while the smearing probably
mice, was observed in postmortem DRPLA brains in results from polyglutamine-mediated aggregation. Col-
cerebellar dentate nucleus, granule cells, and pons (H. lectively, these data suggest that nuclear accumulation
Yamada, personal communication). These data demon- of truncated mutant atrophin-1 protein plays a role in
strate that truncated fragments of mutant atrophin-1 are the evolution of neuropathology in DRPLA.
found in the nuclei of DRPLA patients. The lower levels DRPLA patients have neuronal degeneration in a num-
of the 120 kDa fragments in the patients may reflect ber of brain areas and widespread distribution of ubiqui-
difficulties in subcellular fractionation of human post- tinated neuronal and glial intranuclear inclusions in the
mortem tissue or a loss of affected neurons. brain (Hayashi et al., 1998). Our mutant atrophin-1
transgenic mice show a similar widespread distribution
of nuclear pathology. Although we do not observe se-Discussion
vere degeneration of the dentate of the cerebellum or
globus pallidus, two regions heavily affected in DRPLA,We demonstrate that transgenic mice expressing mu-
tant human atrophin-1 develop a neurologic disorder, it is possible that more subtle losses have occurred.
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Studies are underway using stereologic counting proce- masking in aggregates. The present report provides
evidence of aberrant accumulation and aggregationdures to assess the numbers of neurons in mice at vari-
of truncated fragments of mutant atrophin-1 in a trans-ous ages in relevant neuronal populations. We anticipate
genic mouse model of DRPLA. Seemingly identical frag-that these investigations will determine the extent of
ments were observed in DRPLA patients. An alternativeneuronal loss.
possibility is that the 120 kDa bands represent full-lengthAs has been described in HD and DRPLA patients
atrophin-1 that is not modified in the same way thatand transgenic models of HD (Mangiarini et al., 1996;
atrophin-1 normally is, perhaps because there is less ofDavies et al., 1997; DiFiglia et al., 1997; Becher et al.,
the modifying protein(s) in the nucleus. However, previ-1998; Hayashi et al., 1998; Igarashi et al., 1998; Reddy et
ous studies of atrophin-1, using different antibodies,al., 1998; Schilling et al., 1999), we demonstrate neuronal
have also described it as running at 150±180 kDa (Knightintranuclear inclusions in multiple populations of neu-
et al., 1997; Yazawa et al., 1995; Miyashita et al., 1998).rons in our mutant atrophin-1 mice. These inclusions are
In addition, in vitro transcription and translation alsothought to consist of aggregates of the expanded polyglu-
yield a single band at 150±180 kDa (Miyashita et al.,tamine protein; aggregation may be driven through polar
1997; Wellington et al., 1998).zippers (Perutz, 1995; Scherzinger et al., 1997) and stabi-
Because of the strong correlation between the levelslized by the action of transglutaminases (Igarashi et al.,
of the fragments and the levels of pathologic nuclear1998; Kahlem et al., 1998). Other proteins such as cas-
immunoreactivity, we believe that the generation of thepases, chaperones, proteasomes, and proteins con-
fragments contributes to the evolution of pathology.taining long stretches of glutamines (tata-binding pro-
Preliminary studies in transfected N2a cells suggest thattein [TBP], for example) can be recruited into inclusions
C-terminally truncated atrophin-1 fragments, including(Cummings et al., 1998; Perez et al., 1998; Chai et al.,
65Q, are more toxic to cells than the full-length atrophin-11999; Sanchez et al., 1999; Stenoien et al., 1999). How-
with 65Q (F. Nucifora et al., personal communication).ever, the inclusions per se may not be toxic, and other
Thus, there is reason to believe that the 120 kDa frag-forms of mutant protein may represent the toxic entity
ments may be more toxic than the full-length protein.(Klement et al., 1998; Saudou et al., 1998; Gutekunst et
The nature of the proteolytic event that gives rise toal., 1999).
the 120 kDa mutant fragments has yet to be defined. A
number of polyglutamine proteins, including atrophin-1A Possible Role for Proteolytic Processing in the
and huntingtin, are subject to cleavage in vitro by mem-Pathogenesis of Polyglutamine Diseases
bers of the caspase family of endoproteinases (Gold-Proteolytic processing of polyglutamine proteins has
berg et al., 1996; Wellington et al., 1998; Ellerby et al.,been hypothesized to play a role in the pathogenesis of
1999a, 1999b), and thus the appearance of the frag-disorders caused by expansions of glutamine repeats
ments and their increase in abundance as the mutant(Goldberg et al., 1996; Ikeda et al., 1996; Miyashita et
mice age may be a consequence of cellular dysfunctional., 1997; Ross, 1997; Wellington et al., 1998; Ellerby et
and caspase activation. However, our analysis of theal., 1999a, 1999b). HD postmortem brain appears to
26Q mice indicates that atrophin-1 may normally be
contain truncated fragments of huntingtin (DiFiglia et
subject to proteolytic processing, generating fragments
al., 1997; Becher et al., 1998), which may result from the
of 120 kDa and larger (see Figure 2B). Thus, the produc-
action of caspases (Goldberg et al., 1996; Wellington et
tion of the 120 kDa fragments may be a normal event
al., 1998) or other proteases. In cultured cells, truncated in the processing or degradation of atrophin-1 and not a
fragments of huntingtin and other polyglutamine-con- nonspecific consequence of the activation of proteases
taining proteins are often more toxic and more likely to associated with cell death.
aggregate into polymeric structures (Cooper et al., 1998; An analysis of amino acid sequence motifs in atrophin-1
Martindale et al., 1998; Moulder et al., 1999). Transgenic identified a motif in the N terminus (residues 16±32) with
mice expressing N-terminal fragments of huntingtin de- homology to nuclear localization signals (NLS) and a
velop behavioral and neuropathological features that motif near the C terminus (residues 1033±1041) with
resemble aspects of HD (Mangiarini et al., 1996; Davies homology to nuclear export signals (NES). Immunoblot-
et al., 1997; Schilling et al., 1999). A yeast artificial chro- ting with an N-terminal peptide antibody indicated that
mosome transgenic model of HD has intranuclear hun- the 120 kDa fragments contain the N terminus (J. W.,
tingtin immunoreactivity using antibodies to the N termi- unpublished data). Thus, on the basis of the relative
nus but not to an internal epitope (Hodgson et al., 1999). molecular mass of the 120 kDa fragments, we believe
Collectively, these observations have given rise to the that the putative NES would be removed and that the
toxic fragment hypothesis, whereby smaller proteolytic truncation could alter the normal location of the protein
fragments of expanded polyglutamine proteins con- to favor a nuclear localization. Preliminary studies sug-
taining the glutamine repeat show a greater propensity gest that both the NLS and NES are functional (F. Nuci-
for aggregation and may underlie neuronal dysfunction fora, personal communication).
and the neurological phenotype (Ikeda et al., 1996; One important aspect of our analysis of the 120 kDa
DiFiglia et al., 1997; Ross, 1997; Davies et al., 1998). fragments was the notable increase in their abundance
However, previous studies have seen fragments on in the mutant mice as a function of age. Without knowl-
Western blots only inconsistently (DiFiglia et al., 1997) or edge of the relative half-lives of the full-length mutant
have relied on differential antibody reactivity to different protein and the 120 kDa fragments, it is difficult to know
epitopes by immunohistochemistry (DiFiglia et al., 1997; whether the increased abundance of the fragments as
Becher et al., 1998; Hodgson et al., 1999), which can be the animals age is a consequence of an accumulation
of the fragments over time or increased generation ofdifficult to interpret due to the possibility of antigen
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protein promoter vector (Borchelt et al., 1996). The transgene con-the fragments. We favor a scenario in which truncation
structs were transfected into HEK293 cells, and protein expressionof mutant atrophin-1 creates a molecule that is much
was confirmed by Western blot analysis. The constructs were linear-longer lived than full-length protein because it is (1)
ized with NotI and resolved on a 0.6% low±melting point agarose
preferentially mislocalized to the nucleus and (2) more gel (FMC Bioproducts). The agarose was digested with b-agarase
prone to aggregate into nondegradable structures. In (Epicentre Technologies), and after further purification, DNA was
injected into the male pronucleus of fertilized oocytes. Foundersthis setting, the increase in the abundance of the mutant
were analyzed for insertion of the transgene with a three-way PCR120 kDa fragments as the 65Q mice age would be the
reaction with the following primers: PrP-sense (59-CCTCTTTGTGACconsequence of its accumulation over time.
TATGTGGACTGATGTCGG5±39) and PrP-antisense (59-GTGGATACOur immunocytochemical and biochemical analyses
CCCCTCCCCCAGCCTAGACC-39), which together give a product
of the mutant mice clearly demonstrate that the 120 kDa of 700 bp, and At-3818±59 (59-AGGTGGGGAGGTGGCGAGGAT-39),
fragments are localized to the nucleus. Other studies which gives a transgene-specific product of 400 bp with PrP-anti-
sense in transgenic animals. The copy number was established byhave recently identified the nucleus as a critical site for
probing of a Southern blot of genomic mouse tail DNA with randomtoxicity of polyglutamine proteins (Klement et al., 1998;
prime-labeled BamHI fragments of atrophin-1 (bp 2980±3348). Ani-Saudou et al., 1998; Peters et al., 1999). Ataxin-1 and
mals with more than ten copies were bred into stable transgenicataxin-3 associate with proteins present in the nuclear
lines. The lines were maintained on a hybrid C3H/B6 background
matrix (Matilla et al., 1997; Skinner et al., 1997; Tait et (Jackson Laboratories).
al., 1998). The question arises as to what processes
are affected by the nuclear accumulation of truncated Northern Blot Analysis
Transgene expression in the breeding lines was analyzed by North-atrophin-1 fragments. We have recently found that the
ern blot. Total RNA was prepared from mouse brains with TRIZOLN terminus of atrophin-1 interacts with ETO, a compo-
(BRL), and 5 mg of total RNA was fractionated on a formaldehydenent of nuclear corepressor complexes localized to the
agarose gel. RNA was transferred to a nylon membrane (Gene-nuclear matrix (J. W., unpublished data). This raises the
screen; NEN) and probed with a random prime-labeled BamHI frag-
possibility that the regulation of transcription is altered. ment of human atrophin-1 (bp 2980±3348). The Northern blot was
reprobed with a 32P-labeled fragment of PrP to verify equal loading
of RNA in each lane.
Conclusions
In summary, our study demonstrates that truncated Human Tissue Samples
Frozen pieces of cerebella from the following cases were used.products of mutant atrophin-1 are found in mutant
DRPLA cases: N17(81) (female; 66Q; onset, 8 years; duration, 9transgenic mice and in the cerebella of DRPLA cases.
years), N11(96) (female; 65Q; onset, 14 years; duration, 18 years),The temporal and spatial distribution of these fragments
and N8(98) (male; 67Q; onset, 16 years; duration, 13 years); control
correlates well with the appearance of aberrant nuclear cases: N2(98) (male; death, 56 years) and N28(98) (female; death,
atrophin-1 immunoreactivity and atrophin-1 immunore- 74 years).
active inclusions in the nucleus of multiple neuronal pop-
ulations. Our mutant atrophin-1 transgenic mice repre- Preparation of Nuclei and Cytosol
Brain tissue was homogenized in 15 volumes (w/v) of 0.25 M su-sent a polyglutamine disease animal model that clearly
crose/buffer A (50 mM triethanolamine [pH 7.5], 25 mM KCl, 5 mMdemonstrates proteolytic fragments of the mutant poly-
MgCl2, 0.5 mM dithiothreitol, and 0.5 mM phenylmethylsulfonylglutamine protein. We propose that this is an important
[PMSF], supplemented with Complete protease inhibitor cocktail
event in the evolution of pathological changes. Although tablets [Boehringer Mannheim]) and centrifuged at 800 3 g for 15
the levels of these fragments in human tissues seemed min at 48C. The supernatants were centrifuged at 100,000 3 g for 1
to be lower than the levels in mice, the extent of cell hr at 48C, and the resulting supernatants were taken as the cytosolic
fractions (C). The pellets from the initial centrifugation step wereloss in the human cases may be much greater than in
resuspended in 10 ml each of 0.25 M sucrose/buffer A and thenthe mice, and the expression profiles of the atrophin-1
mixed with 20 ml each of 2.3 M sucrose/buffer A. The resultingand prion protein promotors may differ. Furthermore,
mixtures were layered on top of 10 ml each of 2.3 M sucrose/buffer
nuclear fractionation of postmortem tissues is signifi- A, and then nuclei were pelleted by centrifugation at 12,400 3 g for
cantly more difficult than fractionating fresh tissues from 1 hr at 48C. The pellet was resuspended in 0.25 M sucrose/buffer
the mice. Thus, we believe that the accumulation of A and washed by low-speed centrifugation. The final pellet was
designated as the nuclear fraction (N).the truncated atrophin-1 molecules found in the mutant
mice is an authentic recapitulation of events occurring
Immunoblot Analysisin the human disease. These mice will prove a source
Protein concentrations were assayed by the dye-binding methodof tissue that will help characterize the nature of the
(Pierce) with bovine serum albumin as standard. Cytosol samples
proteolytic processing that generates the 120 kDa mu- were concentrated by trichloroacetic acid precipitation when neces-
tant fragments and for defining the role of these mole- sary, and proteins were solubilized in SDS±PAGE loading buffer at
cules in the pathogenesis of disease. 0.5 mg.ml21. They were then sonicated for 20 s, heated at 708C for
5 min, and microfuged for 1 min prior to loading. Proteins were
resolved by SDS±PAGE in a 6% polyacrylamide-SDS gel at 10 mA
per gel and then transferred to a polyvinylidene difluoride membraneExperimental Procedures
(Schleicher and Schuell). Transfer buffer was 25 mM Tris, 192 mM
glycine, 0.1% SDS, and 10% methanol; the inclusion of SDS inTransgene Construction
Full-length cDNAs of atrophin-1 encoding 26 and 65 consecutive the transfer buffer was found to greatly enhance atrophin-1 signal
strength. Immunoblots were probed with anti-atrophin-1 antibodyglutamines were constructed as described elsewhere (Margolis et
al., 1996). These constructs contain z70 nucleotides of atrophin-1 AP142 (Wood et al., 1998). Bound antibodies were visualized with
horseradish peroxidase±conjugated secondary antibodies and en-59-UTR and z600 nucleotides of 39-UTR. The atrophin-1 cDNAs
were excised with KpnI and XbaI, blunt ended, and flanked with hanced chemiluminescence (Renaissance; NEN). Identically loaded
gels were stained with Coomassie blue to confirm equivalent proteinphosphorylated XhoI linkers (Stratagene; 59-CCGCTCGAGCGG-39).
They were then digested with XhoI and ligated into the mouse prion loadings.
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To analyze the distribution of mutant atrophin-1 expression, suppression of polyglutamine aggregation in vitro. Hum. Mol. Genet.
8, 673±682.mouse brains were dissected on an ice-cold glass plate, and specific
regions from different mice were pooled. The regions were homoge- Cooper, J.K., Schilling, G., Peters, M.F., Herring, W.J., Sharp, A.H.,
nized in 15 volumes (w/v) of 5 mM HEPES (pH 7.4), 0.32 M sucrose, Kaminski, Z., Masone, J., Khan, F.A., Delanoy, M., Borchelt, D.R.,
and 0.1 mM PMSF, supplemented with Complete protease inhibitor Dawson, V.L., Dawson, T.M., and Ross, C.A. (1998). Truncated
cocktail (Boehringer Mannheim). Crude postnuclear (P1) pellets N-terminal fragments of huntingtin with expanded glutamine repeats
were prepared by centrifugation at 500 3 g for 5 min at 48C. These form nuclear and cytoplasmic aggregates in cell culture. Hum. Mol.
were resuspended in one third of the volume of buffer used for Genet. 7, 793±790.
homogenization, assayed for protein concentration, and subjected Cummings, C.J., Mancini, M.A., Antalffy, B., DeFranco, D.B., Orr,
to immunoblot analysis as above. Identically loaded gels were H.T., and Zoghbi, H.Y. (1998). Chaperone suppression of aggrega-
stained with Coomassie blue to confirm equivalent protein loadings. tion and altered subcellular proteasome localization imply protein
Although the mouse prion promoter has been shown to express in misfolding in SCA1. Nat. Genet. 19, 148±154.
heart (Borchelt et al., 1996), atrophin-1 transgene products were
Davies, S.W., Turmaine, M., Cozens, B.A., DiFiglia, M., Sharp, A.H.,
not detected in this tissue by immunoblotting (data not shown).
Ross, C.A., Scherzinger, E., Wanker, E.E., Mangiarini, L., and Bates,
G.P. (1997). Formation of neuronal intranuclear inclusions underlies
Immunocytochemistry the neurological dysfunction in mice transgenic for the HD mutation.
Animals were anesthetized in methoxyflurane (Metofane; Mallinck- Cell 90, 537±548.
rodt Veterinary) and perfused with periodate lysine paraformalde- Davies, S.W., Beardsall, K., Turmaine, M., DiFiglia, M., Aronin, N.,
hyde (PLP) (2% paraformaldehyde, 75 mM lysine, and 10 mM sodium and Bates, G.P. (1998). Are neuronal intranuclear inclusions the
periodate in phosphate-buffered saline [PBS]) through the left car- common neuropathology of triplet-repeat disorders with polyglu-
diac ventricle. The brains were removed, postfixed in PLP overnight, tamine-repeat expansions? Lancet 351, 131±133.
and then transferred to PBS. The brains were cut sagitally and
DiFiglia, M., Sapp, E., Chase, K.O., Davies, S.W., Bates, G.P., Vonsat-
processed for paraffin embedding. Immunostaining of sections (8
tel, J.P., and Aronin, N. (1997). Aggregation of huntingtin in neuronal
mm) was done with AP142 (Wood et al., 1998) at a dilution of 1:10,000
intranuclear inclusions and dystrophic neurites in brain. Science
or 1:25,000 following standard protocols.
277, 1990±1993.
Ellerby, L.M., Hackam, A.S., Propp, S.S., Ellerby, H.M., Rabizadeh,
Rotating Rod Analysis S., Cashman, N.R., Trifiro, M.A., Pinsky, L., Wellington, C.L.,
Six naive animals of lines AT-FL-65Q-150 and AT-FL-26Q-79 and Salvesen, G.S. et al. (1999a). Kennedy's disease: caspase cleavage
six nontransgenic mice were tested on an accelerating rotating rod of the androgen receptor is a crucial event in cytotoxicity. J. Neuro-
(Rotamex 4/8; Columbus Instruments International). The speed of chem. 72, 185±195.
the rod was set to increase from 4 revolutions per min to 40 rev-
Ellerby, L.M., Andrusiak, R.L., Wellington, C.L., Hackam, A.S., Propp,
olutions per min over a 10 min period. The amount of time it took
S.S., Wood, J.D., Sharp, A.H., Margolis, R.L., Ross, C.A., Salvesen,
for the mice to fall from the rod was measured in four trials per
G.S. et al. (1999b). Cleavage of atrophin-1 at caspase site aspartic
day over a 4 day period. At least 10 min of recovery time was
acid 109 modulates cytotoxicity. J. Biol. Chem. 274, 8730±8736.
allowed between trials. The data for each group of animals were
Goldberg, Y.P., Nicholson, D.W., Rasper, D.M., Kalchman, M.A.,averaged.
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